Enhancing Cancer Registries for Early Case Capture of Pediatric and Young Adult Cancer Cases | Apply Online

Frequently Asked Questions (FAQs)

1) What is the title of this grant opportunity?

The opportunity is titled "Enhancing Cancer Registries for Early Case Capture of Pediatric and Young Adult Cancer Cases."

2) Who is offering this funding opportunity?

This funding opportunity is offered by the U.S. Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC).

3) What is the Funding Opportunity Number (FON)?

The Funding Opportunity Number is CDC RFA DP14-140203CONT16.

4) What is the CFDA number and program area associated with this opportunity?

The CFDA number listed is 93.283. The opportunity is categorized under the health funding activity area.

5) What type of award mechanism is this?

This opportunity is structured as a cooperative agreement.

6) What does it mean that this is a cooperative agreement (as opposed to a standard grant)?

Based on the listing description, a cooperative agreement typically indicates the CDC expects substantial involvement in the funded work. In practice, that often means closer coordination with CDC priorities, shared planning and technical direction, and performance expectations tied to public health surveillance outcomes.

7) What is the main purpose of this opportunity?

The purpose is to strengthen cancer registry capacity so that cancer cases in children, adolescents, and young adults are identified and reported more quickly than traditional registry timelines. The intent is to improve the speed and usefulness of cancer surveillance for these younger age groups.

8) What does "early case capture" mean in the context of this opportunity?

In this context, early case capture refers to identifying and reporting pediatric and young adult cancer cases more quickly than traditional cancer registry reporting timelines, so surveillance data for these populations becomes available sooner.

9) Which populations are specifically emphasized by this opportunity?

The opportunity specifically focuses on pediatric and young adult cancer cases, described as cancer in children, adolescents, and young adults.

10) What kinds of systems or capabilities are being enhanced?

The opportunity is aimed at enhancing cancer registries and strengthening registry capacity, with a specific emphasis on improving timeliness of case identification and reporting for pediatric and young adult cancers.

11) Is this a new grant program or a continuation?

The listing identifies this as a continuation cooperative agreement. That suggests it is intended to extend or continue previously funded activities rather than start a brand-new, standalone program.

12) Does "continuation" imply anything about who can apply?

The summary notes that continuation opportunities often support existing awardees or an established project framework. However, the eligibility is not broadly defined in the abbreviated information provided here, so applicants would need to rely on the full announcement text for definitive eligibility rules.

13) What is known about eligibility from the information provided?

Eligibility is listed as "Others (see text field entitled Additional Information on Eligibility for clarification)." This implies eligibility may be limited to specific organization types or existing partners, and that the decisive details are likely located in the full announcement rather than in the summary metadata provided.

14) Where are the detailed eligibility requirements expected to be found?

The summary points to a text field titled "Additional Information on Eligibility" for clarification, indicating that eligibility details would be provided in the full announcement materials rather than the abbreviated listing.

15) When was the opportunity posted?

The opportunity was created and posted on February 24, 2016.

16) What is the application deadline?

The original and current closing date listed is April 22, 2016.

17) Are the original and current closing dates the same?

Yes. The information provided indicates both the original closing date and the current closing date are April 22, 2016.

18) What is the award ceiling for this opportunity?

The award ceiling is listed as 0 in the provided information.

19) What does it mean that the award ceiling is shown as 0?

In the context described, a zero ceiling can appear in continuation announcements or records where funding levels are determined through separate internal allocations, prior-year funding structures, or are specified elsewhere in the full notice rather than in the abbreviated record.

20) How many awards are expected to be made?

The expected number of awards is not provided in the supplied information.

21) Why might the expected number of awards not be listed?

The description notes that missing award counts and funding levels can occur in continuation announcements, amendments, or records where the specifics are handled through other internal allocations or are documented elsewhere in the full announcement.

22) What overall outcomes is CDC trying to support through this opportunity?

The opportunity is designed to support faster reporting and better-informed public health and clinical efforts for pediatric and young adult cancer populations, by improving the timeliness and usefulness of cancer surveillance data.

23) What is the general role of CDC in the funded work?

Because the mechanism is a cooperative agreement, the summary indicates CDC oversight and collaboration are expected, consistent with substantial involvement such as coordinated planning, technical direction, and performance expectations aligned with surveillance outcomes.

24) What is the main focus area: treatment, research, or surveillance?

Based on the title and description provided, the primary focus is surveillance: strengthening cancer registry capacity to identify and report cases sooner for pediatric and young adult populations.

25) Is this opportunity tied to a specific federal department and agency?

Yes. It is offered under HHS, specifically through the CDC.